Aurora Biosciences Licenses Technology From Xenometrix

Dec 17, 1998

Premium

BOULDER, Colo.--Aurora Biosciences of San Diego has gained access to the gene expression profiling technology for which Xenometrix here received a European patent in January. Xenometrix's non-exclusive license covers gene expression profiling utilizing methods other than high-density oligonucleotide microarrays.

Aurora also announced that Paul England has been promoted from vice-president discovery operations to senior vice-president research. England joined Aurora in February after 13 years in pharmaceutical research at SmithKline Beecham.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Main menu